US › Healthcare

Coherus BioSciences Inc (CHRS)

US · Healthcare · Biotechnology

$1.48+2.78%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$12.3M
Revenue YoY
+62.0%
Net profit
$-37.9M
Profit YoY
+32.9%
EPS
$-0.25
EPS estimate
$-0.26
Net margin
-308.2%

EPS came in at -0.25 against a street estimate of -0.26 — a beat of 3.8%.

Key statistics

Market cap
$222.1M
Forward P/E
41.2
P/B
2.75
Book value
$0.51
EPS (TTM)
$-1.42
52-week high
$2.62
52-week low
$0.81
50-day MA
$1.48
200-day MA
$1.60
Beta
0.95

Analyst view

Analysts rate Coherus BioSciences Inc a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $7.80.

Shareholding

Insiders
18.66%
Institutions
38.66%

Largest institutional holders

FundStake
BlackRock Inc6.72%
Vanguard Group Inc6.50%
Vanguard Capital Management, LLC3.54%
Samsara BioCapital, LLC2.22%
Geode Capital Management, LLC2.02%
Kohlberg Kravis Roberts & Co LP1.97%
State Street Corp1.51%
Two Sigma Investments LLC1.49%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Coherus BioSciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.